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Abstract 
Purpose of review: Clozapine has recently been described as a novel cause of secondary antibody 
deficiency (SAD), associated with long-term therapy. Here we critically review the evidence linking 
clozapine-use to an increased infection risk, describe immunological alterations, and discuss potential 
mechanisms. 
Findings: Individuals with schizophrenia are at 2-5 times more likely to develop pneumonia than the 
general population, in particular when receiving clozapine. Delayed-onset distinguishes clozapine-
associated hypogammaglobulinaemia from agranulocytosis or neutropenia that occur at lesser 
frequency. Biomarker searches in treatment-resistant schizophrenia highlight an immu e signature 
associated with long-term clozapine use. This includes reduction in class-switched memory B-cells, 
echoing common variable immunodeficiency. Recent identification of a role for dopamine in T 
follicular helper – B cell interactions may inform future clinical studies.  
Summary: The detrimental impact of the increased infection risk associated with clozapine necessitates 
a re-evaluation of the current monitoring strategies as well as further studies to better understand the 
underlying mechanisms of SAD in this setting. Based on available evidence, we suggest  simple
modifications to clozapine monitoring including integration of routine vaccination, smoking cessation, 
and assessment of humoral immunity. Further studies are required to understand the role of clozapine 
in neuroinflammation as well as potentially other autoantibody mediated diseases.  
Keywords: Clozapine, Hypogammaglobulinaemia, Secondary Antibody Deficiency (SAD), 
Monitoring, Immunoglobulin Replacement Therapy (IgRT). 
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Abbreviations: 
ANC Absolute Neutrophil Count 
CSMB Class-Switched Memory B-cell 
CVID Common Variable Immunodeficiency 
DRD Dopamine Receptor 
HBV Hepatitis B Virus 
IgRT Immunoglobulin Replacement Therapy 
NMDA-R N-Methyl-d-Aspartate Receptor 
REMS Risk Evaluation and Mitigation Strategy 
SAD Secondary Antibody Deficiency 
SMI Severe Mental Illness 
SMR Standardised Mortality Ratio 
TFH T-Follicular Helper  
TRS Treatment Resistant Schizophrenia 
 
Introduction  
Major global causes of secondary immunodeficiency include malnutrition, HIV, and malaria. In this 
review we focus on secondary antibody deficiency (SAD) and in particular the novel association of 
clozapine with SAD. The field of SAD comprises a heterogeneous and expanding group of clinical 
conditions characterized by a persistent impairment of antibody production due to a wide range of 
diseases and drugs. The growth in SAD is to a large extent driven by improvements in the therapies and 
their wider use to treat autoimmunity, inflammation, transplant rejection and m lignancy, especially by 
agents targeting B cells (1). The mechanism(s) of action of the majority of these drugs is 
immunosuppressive while in contrast clozapine, a dibenzodiazepine atypical antipsychotic, used in 
treatment resistant schizophrenia (TRS) does not at first glance fall into this category. Indeed, the 
association of clozapine with SAD was serendipitously discovered as part of population-based 
screening for antibody deficiency using calculated globulin (2-5).  
Clozapine is an important global medication and is one of the World Health Organisation (WHO) 
essential medicines. It represents one of only two major therapeutic advances in th  trea ment of 
schizophrenia in over half a century (chlorpromazine in 1950 and clozapine in 1958) and remains the 
gold standard therapy for TRS (6). Schizophrenia affects around 1% of the population with 30% of 
cases being treatment resistant. It has superior efficacy over other antipsychotic  in reducing both 
positive and negative symptoms and is effective in approximately 60% of previously treatment 
refractive patients with a significant reduction in suicide risk (7, 8). Clozapine can cause serious adverse 
effects including agranulocytosis (cumulative incidence 0.8%) (9, 10); necessitating intensive 
centralised registry-based monitoring systems to support its safe use.  
In 2015 in the United States, the Federal Drug Administration (FDA) merged and replaced the six 
existing clozapine registries combining data from over 50,000 prescribers, 28,000 pharmacies, and 
90,000 patients records into a single shared registry for all clozapine products, the Clozapine Risk 
Evaluation and Mitigation Strategy (REMS) Program (www.clozapinerems.com). Blood testing of 
the absolute neutrophil count (ANC) is initially required weekly in order to receive ongoing clozapine 
therapy. Patients with schizophrenia are a vulnerable group with a number of independent risk fac ors 
for infection in addition to the potential risk of neutropenia.  
The recognition of SAD in this context is important not only because patients receiving long-term 
clozapine form a large and vulnerable group but also to prevent potential life-threatening infections and 
irreversible organ damage, such as bronchiectasis. Early detection allows potential changes in 
monitoring, further immunological assessment or the initiation of therapies to reduce the risks of 
infection such as vaccination, antibiotics or in selected cases immunoglobulin replacement therapy 
(IgRT) (11). 
We will review the evidence supporting an increase in infections, in particula pneumonia, in patients 
taking clozapine, the association with SAD and potential mechanisms. In addition, we describe the 
immunological and clinical features and management of clozapine related antibody deficiency and 
propose an amendment to the current clozapine REMS monitoring schemes to include testing for SAD.
 
 
Infectious Risk and antibody deficiency in Clozapine-treated patients  
Patients with schizophrenia have a 10-20 year reduction of life expectancy compared to th  general 
population (12) with a consistent contribution toward this reduction due to a high risk of respiratory 
infection (Table 1). Patients with chronic psychosis are known to be at greater risk of infection though 
factors such as elevated smoking rates, metabolic disorders, dental caries and poorer integration with 
community health providers (13-17). In a recent study, assessing mortality in people with severe mental 
illness (SMI), the standardised mortality ratio (SMR) was 2.6 higher compared to the general 
population. Schizophrenia patients had the highest SMR of all, with 3.8 times the number of deaths 
observed compared to that expected based on the age- and sex-specific rates for the general population 
(18). Interestingly, 17.8% of deaths were attributable to respiratory disease with mortality for 
pneumonia 3.8-fold higher compared to the general population, with a SMR of 10.7 in subjects younger 
than 45 years. Consistent with this and using a similar retrospective approach, the overall incidence of 
pleural empyema was found to be 2.44-fold greater in schizophrenia than the general population (19). 
Increasing evidence has highlighted clozapine as the antipsychotic drug most strongly associated with 
pneumonia risk (20-24). Current users of clozapine alone were twice as likely to develop pneumonia, 
and use of clozapine combined with other antipsychotics (olanzapine, quetiapine, zotepine, risperidone, 
or amisulpride) was associated with even greater risk (25). Moreover, although all of the antipsychotics 
with the exception of amisulpride were significantly associated with increased risk of pneumonia in the 
first 30 days of use, clozapine had the highest risk-increase both in this interval and long term (25). In 
keeping with this data, a higher use of antibiotics compared to clozapine-naïve schizophrenia control 
patients was described in a cohort study including clozapine-treated patients drawn from Danish Central 
Psychiatric Research Registry (26). It is important to consider the limitations of epidemiological studies 
to date; for instance, analysis of both the Danish (26) and Taiwanese Registries (19, 25) lacked 
information on smoking, drinking, nutrition, and social-deprivation status. Socio-economic drift is well-
recognised in association with schizophrenia (8) and is plausibly exaggerated in tr atment-resistant 
patients.  
In testament to the efficacy of clozapine in the treatment of schizophrenia, a systematic review including 
24 studies reported lower mortality rate ratios in patients continuously treated with clozapine compared 
to other antipsychotics (27). This finding could reflect the effectiveness of clozapine in increasing the 
overall level of function, thus leading to the improvement in a number of risk factors linked to lifestyle, 
cardiovascular disease and reduction in suicide rates (27, 28). However, as this systematic review did 
not stratify mortality rate ratios based on the cause of death it was not possible to analyse data on the 
impact of respiratory infections in clozapine-treated patients. Overall, this suggests that reducing 
infection-related mortality could further enhance clozapine’s efficacy. 
The relationship between infection, clozapine use, and adverse events are likely to b  complex and 
multi-factorial. Various mechanisms for the increase in infectious risk in clozapine-treated patients have 
been suggested including smoking, sedation, agranulocytosis, diabetes, alcohol intake, illicit drug use, 
poor diet and physical inactivity, sialorrhoea, aspiration and, most recently, antibody deficiency (29, 
30). The impact of clozapine on antibody deficiency was investigated in a cross-sectional case-control 
study comparing immunological and clinical features of schizophrenia patients takig either clozapine 
or other antipsychotics (5). Clozapine-treated patients showed a significant reduction of all three 
immunoglobulin classes (IgG, IgA and IgM) compared to clozapine-naïve group. In particular, 8.5% of 
clozapine-treated patients versus 1% of controls had IgG serum levels below the lo er limit of the 
reference range (6.0 g/l); 13.8% of clozapine-treated versus no controls had low IgA levels (<0.80 g/L); 
and 34% of clozapine-treated versus 15.3% of control group had low IgM levels (<0.50 g/L). 
Interestingly, a significant association was found between clozapine treatment duration and the degree 
of reduction in IgG serum levels, with an annual decline of serum IgG by 0.15 g/L, thus suggesting a 
cumulative effect of clozapine on antibody production (Figure 1). This was despite identification and 
exclusion of possible secondary causes of hypogammaglobulinaemia with additional linear regression 
analysis to control for possible effect of diagnoses (e.g. asthma or chronic obstructive pulmonary 
disorder) associated with use of medications with potential immunosuppressive effects (e.g. 
glucocorticoids) not documented in available psychiatric or electronic healthcare records. In a dition, 
although no differences in levels of specific IgG against haemophilus influenzae B, pneumococcus, and 
tetanus were observed between the two study-groups, clozapine-treated patients had a significant 
reduction of pneumococcal-specific IgA and IgM, perhaps reflecting the observed greater relative 
reductions in total IgA and IgM levels. Immunological abnormalities were mirrored by the clinical 
history: clozapine-receiving patients had higher antibiotic use, with 5.3% patients reporting more than 
five antibiotic courses per year versus 1% in clozapine-naïve group. Taken together th  data suggest 
both a quantitative and qualitative impairment of antibody production associated with clozapine 
accompanied by an increase in infection susceptibility. 
Immunological alterations and possible pathogenetic mechanisms  
Disturbances of innate immunity associated with clozapine are well described and include transient 
fever and eosinophilia with a small proportion (<1%) developing neutropenia or agranulocytosis (31-
35). Of note, clozapine-induced fever characteristically appears around 10-14 days following initiation, 
thus might erroneously contribute to the early spike in pneumonia detection rates discus ed above (25). 
Here we focus on adaptive immune disturbances associated with clozapine therapy.  
To date, only one study has been reported using multi-parameter flow cytometry to compare TRS 
patients with healthy volunteers (36). The observed differences include a shift towards naïve B-cell 
populations, with reduction in plasmablast (CD3-CD19+IgD-CD20+CD38+) and class-switched memory 
B (CSMB; CD3-CD19+IgD-CD27+) populations. Importantly, 17 of the 18 TRS patients tested had 
received clozapine therapy with a mean duration of 18 years. Thus, this search for biomarkers of TRS 
potentially highlights a distinctive immunophenotype of long-term clozapine therapy. Reduced CSMB 
populations are predictive of immunoglobulin replacement requirement in secondary 
hypogammaglobulinemia (37). This is in keeping with our initial report (5), and we have independently 
noted marked a reduction in class-switched memory B-cell populations and plasmablast frequencies 
among clozapine-treated patients referred clinically based on calculated globulin screening (manuscript 
in submission). Within our cohort of patients requiring immunoglobulin replacement therapy (IgRT) 
for hypogammaglobulinemia and infection, 7 patients with a diagnosis of schizophrenia of which 6 
have a history of clozapine therapy. This raises diagnostic challenges as the constellati  of 
hypogammaglobulinemia, infection susceptibility, and low CSMB, are core defining a d diagnostic 
features of common variable immunodeficiency (CVID) (38, 39). We are currently conducting a survey 
of Immunodeficiency Centres to define immunological phenotype in clozapine-treated pati nts across 
the UK. 
Immunophenotyping also revealed heightened expression of DRD3 on peripheral HLA-DR+ memory 
T- and regulatory T-cells in clozapine-treated patients (36). Interplay between neuronal and immune 
systems has long been recognised (40) and has led to novel therapeutic avenues (41-43). Recently, Papa 
et al have identified dopamine synthesis occurs within T-follicular helper cells (TFH) of the germinal 
centre (44). Dopamine release from TFH granule stores is triggered by cognate interaction with B-cells. 
This acts on the B-cell to stimulate rapid deployment of pre-formed ICOS-ligand to the cell surface, 
supporting rapid co-stimulation and resulting in CD40L upregulation on the TFH cell (44). Thus, 
dopamine signalling contributes to a feedforward co-stimulatory loop facilitating T-B cell interactions 
(Figure 2). Dopamine synthesis is not detectable within murine T-cells, suggesting this mechanism has 
arisen later in evolution. Therefore, computational modelling, instead of conventional murine studies, 
have been used to predict this mechanism significantly enhances germinal centre output but has little 
impact on affinity maturation (44).  
Could antagonism of germinal centre dopaminergic signalling by antipsychotics underlie clozapine-
associated hypogammaglobulinaemia? Whilst certainly an attractive explanation, Papa et al found 
DRD1 to be the dominant receptor type expressed by human tonsillar B-cells. Based on receptor binding 
affinities (45), this would predict a class effect for antipsychotics over a clozpine-specific mechanism. 
Indeed, both haloperidol and a DRD1-specific antagonist were able to block ICOS-L upregulation in 
vitro (44).  Nevertheless, previous studies of human B cells have reported frequent expression of both 
DRD1 and DRD2 (46), and differences between B-cells within blood, lymphoid, and tonsillar tissue are 
well recognised (47). Extrapolation from these insights is also complicated by changing patterns of 
dopamine receptor expression following antipsychotic exposure (48). Despite such limitations, th s 
work directly raises clinically relevant questions. Do individuals receiving antipsychotics differ in their 
ability to mount and sustain a response to vaccination from antipsychotic-naïve individuals? How do 
different antipsychotics vary in their impact?  
We previously demonstrated reduction in serum IgM levels relative to the normal adult range level, and 
low concentrations of specific IgG to frequently encountered vaccinations, are common across anti-
psychotic treated individuals with schizophrenia (5). These results are difficult to interpret in isolation 
however, as access and uptake of vaccinations is often lower than for those with serious m ntal illness 
(49). Remarkably, despite intense interest in the role of early-life infection in the aetiology of psychosis, 
and convergent evidence indicating an elevated risk of pneumococcal disease (19), few large-sca e 
studies have considered this issue to date. An Ovid Medline Search conducted 28th June 2019 using the 
terms “vaccine OR vaccination” AND “schizophrenia OR psychosis” identified only one major case 
series in which 175 institutionalised psychiatric patients received Hepatitis B virus (HBV) vaccination. 
This concluded vaccine response rates were significantly lower than expected for healthy individuals 
(50). A subsequent case-control study of 415 Chinese schizophrenia patients also found a greater rate 
of HBV infection in those receiving clozapine, even in those who had received routine immunization 
(51). Historical studies containing small numbers of patients showed mixed results for vaccination 
responses (52, 53). 
Neuroinflammation and immunosuppressive effects of clozapine: two sides of the same coin? 
Recognition of anti-neuronal antibodies underlying acute psychosis provides the clearest evidence for 
the role of autoimmunity in psychiatric disease (54). Antibodies to N-methyl-d-aspartate receptor 
(NMDA-R) are detectable in approximately 3% of patients with first-episode psychosis, when tested 
within 6 weeks of commencing antipsychotics (54). Early diagnosis directs treatments to remove 
autoantibodies and halt production to induce remission (55). It has been suggested TRS may represent 
an enriched patient cohort with respect to the presence of anti-neuronal antibodies (56). A smaller study 
identified anti-NMDA-R antibodies in 3 of 43 patients (7%) with chronic treatmn -resistance psychosis 
(57). Intriguingly, in 2 cases, treatment with clozapine resulted in both symptomatic remission and 
resolution or reduction of autoantibody-titres, whilst the 3rd patient elected to remain on quetiapine 
with persistence of symptoms (57). Recent insights suggest ongoing germinal centre reactions are 
essential for anti-NMDA-R autoantibody production (58). Further studies to assess the ability of 
clozapine to influence this are suggested, for instance utilising recently developed murine odels (59). 
Based on current auto-antibody prevalence information however, it seems unlikely that an effect 
targeting anti-neuronal antibodies alone underlies clozapine’s superior efficacy.  
Evidence of neuroinflammation in the pathophysiology of schizophrenia is growing. Microglial 
activation is observed in patients with schizophrenia and those at ultra-high risk of psychosis (60). 
Similarly, induction of neuro-inflammation by administration of a viral mimetic (polyI:C) leads to 
microglial activation and progressive cognitive impairment in rodents – an effect reversed by clozapine 
(61). Wider models of neuroinflammation support clozapine’s efficacy in amyloid-plaque related 
neuroinflammation (62) and highlight its superiority to other antipsychotics in ameliorating 
experimentally induced encephalitis (63). These illuminate potential mechanisms including AMPK-
activation (62) and induction of autophagy (64, 65). Autophagy is a key homeostatic process balancing 
synthesis, degradation/detoxification, and recycling of cellular components (66). Whilst a universal 
cellular process, autophagy plays a non-redundant role in B-cell development and homeostasis (65, 67), 
inflammasome activity (68), and appears dysregulated in schizophrenia (69): highlighting it as an 
important avenue for future research linking clozapine’s therapeutic and adverse effects. 
Management of Clozapine associated antibody deficiency  
The nature, timing, and incidence of neutropenia and agranulocytosis have shaped clozapine risk 
monitoring programmes internationally. Within the first 6 months of clozapine’s introduction to 
Finland, 17 patients developed blood dyscrasias including 8 fatal cases of agranulocytosis due delayed 
recognition and secondary infection. Now almost 3 decades since its re-in roduction, the “no blood, no 
drug” policy is well established with emphasis on the initiation period (70). Recent changes to the US 
clozapine REMS programme support widening access and reduced monitoring intensity requirement 
for clozapine. Currently, requirements are for a weekly absolute neutrophil count assessment from 
initiation to 6 months, every 2 weeks from 6 to 12 months, then monthly after the first 12 months- 
reflecting a 10-fold decrease in agranulocytosis risk after this point (33, 71). Studies modelling safety 
and cost have not considered clozapine-associated hypogammaglobulinemia (72, 73). Evidence 
suggests the magnitude of reduction in immunoglobulins is comparable, if not greater, th n that 
described following long-term combination therapy with rituximab and methotrexate for rheumatoid 
arthritis (based on pooled data from the rituximab clinical trials programme) (74). Post-rituximab 
immunoglobulin reduction is associated with increased risk of recurrent infectio (75, 76). Based on 
these observations, we propose the incorporation of antibody testing within a clozapine risk assessment 
matrix as infrequent (vs rare) but with moderate (vs high) risk of adverse outcome (compared to 
agranulocytosis). In general for SAD, the likelihood of requiring IgRT is inverse to IgG levels (11). We 
therefore suggest changes to clinical monitoring (Fi ure 3). This would begin with documentation of a 
clinical infection history (including e.g. antibiotic course requirements over past 6 months) and 
establishing a baseline for humoral immunity early after psychosis onset. Serum sampling at this time 
also allows exclusion of treatable autoimmune causes (54). An integrative approach to mental and 
physical health should also include measures to improve rates of smoking cessation and vaccination to 
reduce pneumonia and chronic lung disease risk. We suggest seasonal influenza and pneumococcal 
vaccination protocols as per national guidance for “at risk” populations (77, 78). Given an increased 
risk of vaccine preventable hepatitis in this often institutionalized population group (50, 51), we also 
suggest HBV vaccination with subsequent response evaluation. Our experience of clozapine-associated 
hypogammaglobulinemia patients supports a stepwise approach to management including considerati  
of standby antibiotics and regular prophylaxis depending on the frequency and severity of infections. If 
a significant infection burden remains despite prophylactic antibiotics on a background of 
hypogammaglobulinaemia and impaired vaccine responses, IgRT should be considered. 
Following clozapine withdrawal, we have observed a slow recovery of immunoglobulin levels but rapid 
return of schizophrenic symptoms - suggesting a separation of mechanism. In practice, close liaison 
with the patient, psychiatry and immunology teams supports individualised therapy. Immunoglobulin 
replacement therapy to reduce infection frequency is feasible in this patient population (m nuscript in 
submission). Future studies are required to define the health economic impact of extending current
monitoring to include total and vaccine-specific immunoglobulin assessment, enabling cost 
consequence analysis of the excess infection-related healthcare burden attributable to clozapine-
associated hypogammaglobulinaemia. 
Conclusions   
Premature mortality is a feature of this schizophrenia and undermines clozapine’s unique therapeutic 
efficacy. Clozapine-associated secondary antibody deficiency has only recently been describe . 
Humoral dysfunction may contribute the observed sinopulmonary infection related morbidity an  
mortality. Our understanding of mechanism remains limited. Early recognition and treatment are likely 
to improve long-term outcome and quality of life of schizophrenia patients by enabling monitoring and 
interventions to reduce infection susceptibility. We therefore suggest a structured approach to 
assessment and risk mitigation, including introduction of routine vaccination and antibody testing to 
routine clinical care. Larger studies are needed to evaluate the impact of dose, concomitant medications 
and duration and their interaction with genetic and environmental factors (e.g. smoking) on 
development of antibody deficiency and the overall risk of sinopulmonary and other infection. 
Mechanistic insights to clozapine’s unique therapeutic efficacy promise to reveal new approaches to 
combating neuroinflammation and potentially inflammation in a wider context.  
Key Points: 
 Clozapine treatment is associated with a 2-5 fold increase in pneumonia risk for patients with 
schizophrenia relative to the general population or alternative antipsychotic users. 
 Clozapine associated hypogammaglobulinaemia has been recently described as a treatable 
cause of sinopulmonary infection susceptibility.  
 Dopamine signalling contributes to T follicular helper and B-cell interactions within the 
germinal centre suggesting antipsychotics may impair the adaptive humoral response. 
 An integrated approach improving access to healthcare including smoking cessation, access to 
vaccination, and evaluation of immune functionality beyond neutrophil testing is suggested. 
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Figure 1: Effect of duration of non-clozapine antipsychotic (upper) or clozapine (lower) 
treatment on immunoglobulin IgG levels.  
 
No correlation was seen with serum IgG level and non-clozapine antipsychotic medications (P = 0.14) 
despite a longer duration on therapy. A significant negative correlation of duration of clozapine use 
(years) was observed with an annual reduction in IgG levels of 0.15 g/L (P = 0.03). Straight lines show 
predicted IgG at different durations of treatment (in years), based on fitted linear models. Shaded 
regions display pointwise 95% confidence intervals. Dotted lines indicate normal range for IgG 6.0-
16g/L. Reproduced with permission from (5). 
 
  
Figure 2: Dopa i e’s actio s withi  the ger i al ce tre (based on (44))  
 
`  
  
1: Antigen presentation by B-cell stimulates dopamine 
release from T-follicular helper cell 
 
2: Dopamine acts via cell-surface receptors, triggers ICOS 
trafficking from intracellular stores to the B-cell surface 
 
3: ICOS ligand - ICOS interaction provides co-stimulatory 
signal for the TFH cell 
 
4: CD40L- CD40 interaction stimulates B-cell survival 
and differentiation  
Image created by MP using Biorender tool. 
Figure 3: Suggested flowchart for monitoring of humoral immunity during clozapine therapy 
 
Table 1: Mortality and risk of pneumonia in schizophrenia. 
Selected cohort studies investigating overall mortality, pneumonia-related mortality, and risk 
of pneumonia across schizophrenia and specifically clozapine-treated patients. Studies 
concerning other indications for antipsychotic prescription were excluded. Note studies differ 
in study design, population analysed, outcome considered and statistical methods, thus limiting 
comparison of results. SMR = standardized mortality rate; MRR = mortality rate ratio; AHR = 
adjusted hazard ratio; HR = hazard ratio; OR = odds ratio; RR = relative risk; ARR = adjusted 
risk ratio.  
Study Year Outcome Stat
in
Overall Mortality in Schizophrenia 
John et al.  
(18) 
2018 Overall mortality in schizophrenia compared to general population 
Hayes et al. 
(17) 
2017 Overall mortality in schizophrenia compared to general population 
Pneumonia Risk and Mortality in Schizophrenia 
John et al. (18) 2018 
Mortality for pneumonia in schizophrenia compared to general 
population 
Shen et al (79) 2017 
Risk of pleural empyema in patients with Taiwanese patients with 
schizophrenia relative to matched control group from general 
population. 
Seminog et al 
(19) 
2013 
Rates of pneumococcal pneumonia in England based on linked hospital 
episode statistics  
Chou et al. 
(16) 
2013 
Risk of pneumonia in schizophrenia compared to general population  
Mortality for pneumonia in schizophrenia compared to general 
population 
Overall Mortality in Clozapine-treated Schizophrenia 
Vermeulen et al.  
(27) 
2018 
Overall mortality in clozapine-treated compared to clozapine-naïve 
schizophrenia patients 
Tiihonen et al. 
(28) 
2009 
Overall mortality in clozapine-treated compared to clozapine-naïve 
schizophrenia patients 
Risk of Pneumonia in Clozapine-treated Schizophrenia 
Stoecker et al. 
(20) 
2017 Risk of pneumonia in clozapine-treated compared to general population 
Kuo et al. 
(25) 
2013 
Risk of pneumonia in clozapine-treated compared to clozapine-naïve 
schizophrenia patients 
Risk of pneumonia in patients treated with clozapine + any other 
antipsychotic compared to clozapine-naïve schizophrenia patients 
Haddad et al. 
(24) 
2013 
Risk of pneumonia in clozapine-treated compared to no-drug-use 
controls 
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Response to reviewers: ACI190611 
Tha k you for the re ie er’s ki d a d helpful co e ts 
We have adjusted the text to reflect the limitations of epidemiological studies to date, highlighting 
social drift as a potential confounding variable accompanying clozapine therapy.  
 
I look forward to reading the manuscript in press on the immunologic flow cytometry changes in the 
B cell compartment among clozapine-treated patients.  
-Thank you, this is currently with reviewers. 
The data discussed showed low IgG levels in clozapine treated patients, are there data associating 
these IgG levels with infection? Do the authors anticipate similar effects to what is noted in 
antiseizure medications and hypogammaglobulinemia? Is there data correlating IgG levels and 
infection risk in this population? 
We ha e added so e additio al detail o er i g this study to stir the reader’s i terest:  Withi  our 
cohort of patients requiring immunoglobulin replacement therapy (IgRT) for 
hypogammaglobulinemia and infection, 7 patients with a diagnosis of schizophrenia of which 6 have 
a history of clozapine therapy. 
The proposal for Igs/ specific vaccination titers testing in Clozapine treated patients seems 
reasonable. Would the authors dare discuss the potential opportunity of a cost analysis? Would be a 
study i  a d of itself…. 
This is in fact part of an active submission. We have amended the text to: include total and vaccine-
specific immunoglobulin assessment, enabling cost consequence analysis of the excess infection-
related healthcare burden attributable to clozapine-associated hypogammaglobulinaemia. 
 
Minor changes: 
 
Table 1: 
Re o e u derli ed sectio :  Risk of pleural e pye a i  patie ts ith Tai a ese patie ts ith 
schizophre ia relati e to atched co trol group fro  ge eral populatio  
We regret we could not identify an underlined section but would be happy to edit this if it still 
appears within revised version. 
 
Figure 2: 
Numbers 1, 2, 3 and 4 are missing from the figure 
Thank you, we have updated this in the revised version 
 
Figure 3: 
Is S. Typhi antibody titers a routine analysis recommended for adults with hypogammaglobulinemia? 
Similarly HIB titers are commonly collected in children, should they also be collected in adults? 
Our e tre’s pra ti e is to ake use of a o i atio  of a i atio  responses (including Hib and S 
typhi), however in light of recent surveys (e.g. UKPIN) we recognise variation in practice exists. This is 
eyo d the s ope of this re ie , a d e ha e a e ded the Figure to refere e Jolles et al: Whe  to 
initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin 
Exp Immunol. 2017;188(3):333-41  hi h pro ides a ore o plete dis ussio . 
MS Check Form (Editorial Office Use only)
Figure 1
Figure 2 - v0.8
Figure 3 - v0.8
Table 1. Mortality and risk of pneumonia in schizophrenia. 
Cohort studies investigating overall mortality, mortality for pneumonia and risk of pneumonia in all schizophrenia or cloz pine-treated patients 
compared to general population or clozapine-naïve patients. Various studies differ in study design, population analysed, outcome considered and 
statistical methods, thus limiting comparison of results. SMR = standardized mortality rate; MRR = mortality rate ratio; AHR = adjusted hazard 
ratio; HR = hazard ratio; OR = odds ratio; RR = relative risk; ARR = adjusted risk ratio. 
Study Year Outcome 
Statistical 
indicator Result 95% C.I. 
Overall Mortality in Schizophrenia 
John et al.  
(1) 
2018 Overall mortality in schizophrenia compared to general population SMR 2.9 2.8-3.0 
Hayes et al. 
(2) 
2017 Overall mortality in schizophrenia compared to general population HR 2.08 1.98-2.19 
Pneumonia Risk and Mortality in Schizophrenia 
John et al. (1) 2018 
Mortality for pneumonia in schizophrenia compared to general 
population 
SMR 3.8 3.5-4.2 
Shen et al (3) 2017 
Risk of pleural empyema in Taiwanese patients with schizophrenia 
relative to matched control group from general population 
AHR 2.87  2.14 - 3.84 
Table 1 - v0.8
Seminog et al 
(4) 
2013 
Rates of pneumococcal pneumonia in England based on linked hospital 
episode statistics  
RR 2.5 1.9-3.2 
Chou et al. 
(5) 
2013 
Risk of pneumonia in schizophrenia compared to general population  HR 1.77 1.67-1.88 
Mortality for pneumonia in schizophrenia compared to general 
population 
HR 1.39 1.29-1.50 
Overall Mortality in Clozapine-treated 
Vermeulen et al.  
(6) 
2018 
Overall mortality in clozapine-treated compared to clozapine-naïve 
schizophrenia patients 
MRR 0.56 0.36-0.85 
Tiihonen et al. 
(7) 
2009 
Overall mortality in clozapine-treated compared to clozapine-naïve 
schizophrenia patients 
AHR 0.74 0.6-0.91 
Risk of Pneumonia in Clozapine-treated 
Stoecker et al. 
(8) 
2017 Risk of pneumonia in clozapine-treated compared to general population OR 4.07 2.25-7.36 
Kuo et al. 
(9) 
2013 
Risk of pneumonia in clozapine-treated compared to clozapine-naïve 
schizophrenia patients 
ARR 2.01 1.54-2.61 
Risk of pneumonia in patients treated with clozapine + any other 
antipsychotic compared to clozapine-naïve schizophrenia patients 
ARR 4.78 3.68-6.23 
Haddad et al. 
(10) 
2013 
Risk of pneumonia in clozapine-treated compared to no-drug-use 
controls 
RR 3.18 2.62-3.86 
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